Elanco Animal Health (NYSE:ELAN) CFO Purchases $150,398.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CFO Robert Vanhimbergen acquired 6,950 shares of the stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $21.64 per share, with a total value of $150,398.00. Following the transaction, the chief financial officer directly owned 124,233 shares in the company, valued at approximately $2,688,402.12. This represents a 5.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elanco Animal Health Stock Performance

Shares of ELAN traded up $0.43 during trading hours on Monday, reaching $21.72. 5,970,920 shares of the company traded hands, compared to its average volume of 5,860,102. The business has a fifty day moving average price of $21.73 and a 200-day moving average price of $18.10. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $10.79 billion, a P/E ratio of 361.98, a P/E/G ratio of 2.89 and a beta of 1.86. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $23.70.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.13 earnings per share. The firm’s revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ELAN. Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 8th. Finally, JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.78.

Institutional Trading of Elanco Animal Health

A number of institutional investors have recently modified their holdings of the business. Cetera Investment Advisers increased its stake in Elanco Animal Health by 7.2% in the 1st quarter. Cetera Investment Advisers now owns 33,234 shares of the company’s stock valued at $349,000 after purchasing an additional 2,230 shares in the last quarter. LPL Financial LLC boosted its position in shares of Elanco Animal Health by 23.8% in the 1st quarter. LPL Financial LLC now owns 199,595 shares of the company’s stock worth $2,096,000 after buying an additional 38,412 shares in the last quarter. US Bancorp DE grew its position in shares of Elanco Animal Health by 18.7% in the first quarter. US Bancorp DE now owns 14,906 shares of the company’s stock valued at $157,000 after purchasing an additional 2,346 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Elanco Animal Health by 14.0% during the first quarter. PNC Financial Services Group Inc. now owns 13,404 shares of the company’s stock worth $141,000 after buying an additional 1,641 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Elanco Animal Health by 3.5% in the 1st quarter. Invesco Ltd. now owns 555,262 shares of the company’s stock valued at $5,830,000 after purchasing an additional 18,871 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.